Loading...
•
Sep 30, 2023
Krystal Biotech Q3 2023 Earnings Report
Krystal Biotech's Q3 2023 performance was marked by the successful commercial execution of VYJUVEK, progress in the oncology program, and continued momentum in the CF program.
Key Takeaways
Krystal Biotech reported its Q3 2023 financial results, featuring $8.6 million in VYJUVEK U.S. net product revenue, alongside advancements in their clinical programs for CF and oncology. The company closed the quarter with a strong cash position of $598.6 million.
Achieved $8.6 million in VYJUVEK U.S. net product revenue.
Received 284 VYJUVEK Patient Start Forms from 136 unique prescribers.
Advanced the oncology program with first patient dosed in Phase 1 Clinical Trial of KB707.
Closed the quarter with $598.6 million in cash, cash equivalents and investments.
Krystal Biotech
Krystal Biotech
Forward Guidance
Krystal Biotech is focused on several key initiatives, including the potential approval of B-VEC in the EU and Japan, continued clinical trials for various programs, and the advancement of their oncology pipeline.
Positive Outlook
- Anticipates potential B-VEC approval in the EU in the second half of 2024.
- Intends to file a Japanese New Drug Application for B-VEC for DEB in the first half of 2024.
- Expects to announce data from the Phase 1 study of KB407 in 2024.
- Plans to dose the first patient in the Phase 1 clinical trial of KB408 in the first quarter of 2024.
- Plans to initiate the Phase 2 cohort of the KB105-02 (JADE-1) trial in 2024.
Challenges Ahead
- Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals.
- Availability or commercial potential of VYJUVEK or product candidates.
- Sufficiency of cash resources and need for additional financing.
- Risk Factors in the Company’s annual and quarterly reports on file with the SEC.
- Potential delays in clinical trial timelines.